Clinical Trial Update: Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating garetosmab in Japanese adults with fibrodysplasia ossificans progressiva was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrodysplasia Ossificans Progressiva

Drugs mentioned

• Garetosmab (Garetosmab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO) | Phase 3 | Status: WITHDRAWN